Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT03152617
Recruiting Observational

BASUN - Risks for Malnutrition, Metabolic Bone Disease and Impaired Oral Health After Obesity Treatment

NCT03152617 · tracked via the Priya Life Science Sweden tracker
Sponsor
Göteborg University
Phase
Observational
Started
2015-04
Last updated
2025-04-23

Condition(s) studied

Obesity, Morbid

Study summary

Weight-reducing obesity surgery (OS) generally gives good results but complications are common; e.g. impaired weight loss, weight regain, bowel pain, diarrhea, vitamin/mineral deficiency, osteoporosis and impaired dental health. The BASUN study is a prospective 10-year comparison of 1000 surgically and 400 conventionally treated individuals regarding adverse side-effects, risk factors for complications and poor outcome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All patients eligible for obesity treatment under specialist care with medical methods or with surgery Exclusion Criteria: * no ability to speak, read or write in Swedish

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Gastrosurgical R & E, the Sahlgrenska Academy,University of Gothenburg Gothenburg Sweden Recruiting

More Göteborg University trials in Sweden

Transcutaneous Electrical Nerve Stimulation for Endometriosis-related Chronic Pain Recruiting
Early Accessible Person-centred Rehabilitation for Patients With Chronic Pain Recruiting
Bypass Equipoise Sleeve Trial (BEST) Active, not recruiting
OSU6162 in Bipolar Depression (OBID) Recruiting
Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study Active, not recruiting

Other trials for the same condition

Postoperative Nausea, Vomiting and Pain After Bariatric Surgery - a National Registry Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03152617 on ClinicalTrials.gov ↗ ← All trials in Sweden